Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
New England Journal of Medicine · 22.01.2026 · 394 (4) · 354-366
DOI: 10.1056/nejmoa2508959 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 22.01.2026. Verfasst von Sara M Tolaney und 20 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber Cancer Institute, Harvard Medical School, Boston. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Triple Negative Breast Neoplasms, Immunoconjugates. Die Arbeit wurde bisher 104-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Gilead Sciences, Inc.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Dana-Farber Cancer Institute, Harvard Medical School, Boston.
- Institut Jules Bordet, Hôpital Universitaire de Bruxelles and Université Libre de Bruxelles, Brussels.
- Winship Cancer Institute, Emory University, Atlanta.
- Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
- Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
- University of Texas M.D. Anderson Cancer Center, Houston.
ORCID-Profile: Evandro de Azambuja, Clinton Yam, Barbara Pistilli
Förderung
- Gilead Sciences, Inc
Zitieren
APA
Tolaney, S. M., de Azambuja, E., Kalinsky, K., Loi, S., Kim, S. B., Yam, C., Rapoport, B., Im, S. A., Pistilli, B., Mchayleh, W., Cescon, D. W., Watanabe, J., Bañuelas, M. A. L., Freitas-Junior, R., Salvador Bofill, J., Afshari, M., Gary, D., Wang, L., Lai, C., …, & ASCENT-04/KEYNOTE-D19 Clinical Trial Investigators (2026). Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer. New England Journal of Medicine, 394(4), 354-366. https://doi.org/10.1056/nejmoa2508959
Vancouver
Tolaney SM, de Azambuja E, Kalinsky K, Loi S, Kim SB, Yam C, et al. Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer. New England Journal of Medicine. 2026;394(4):354-366. doi:10.1056/nejmoa2508959
BibTeX
@article{Tolaney2026,
author = {Tolaney, Sara M and de Azambuja, Evandro and Kalinsky, Kevin and Loi, Sherene and Kim, Sung-Bae and Yam, Clinton and Rapoport, Bernardo and Im, Seock-Ah and Pistilli, Barbara and Mchayleh, Wassim and Cescon, David W and Watanabe, Junichiro and Bañuelas, Manuel Alejandro Lara and Freitas-Junior, Ruffo and Salvador Bofill, Javier and Afshari, Maryam and Gary, Dianna and Wang, Lu and Lai, Catherine and Schmid, Peter and ASCENT-04/KEYNOTE-D19 Clinical Trial Investigators, ASCENT-04/KEYNOTE-D19 Clinical Trial Investigators},
title = {Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer},
journal = {New England Journal of Medicine},
year = {2026},
volume = {394},
number = {4},
pages = {354--366},
doi = {10.1056/nejmoa2508959}
}
EUVIMED